Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Watchman Prevail With FDA? Boston Scientific’s LAA Closure Trial Raises Questions, Controversy

Executive Summary

The PREVAIL study of Boston Scientific’s Watchman left atrial appendage (LAA) closure device was primarily positive, but will it be enough to win FDA approval for the device?

You may also be interested in...



HRS 2014 Roundup

The 2014 Heart Rhythm Society Scientific Sessions ended May 10 in San Francisco with a big study from Boston Scientific on the benefits of implantable cardioverter defibrillator remote monitoring, and data on a smartphone-enabled electrocardiogram and the use of a spinal stimulator for heart failure patients. Earlier in the meeting, data were reported on the success of pacemaker remote monitoring and other studies.

HRS Round-Up: Remote Pacemaker Monitoring Improves Survival

Results of a St.Jude-sponsored trial of remote pacemaker monitoring was the highlight of the first two days of new clinical trial data presented at the Heart Rhythm Society annual scientific sessions in San Francisco.

Two Approaches To Attacking Left-Atrial Appendage To Stop AFib

Studies in the Journal of the American College of Cardiology look at outcomes with St. Jude Medical's Amplatzer Cardiac Plug and SentreHeart’s Lariat suture-delivery device.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT035613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel